Results Data were collected for 51 patients (63% female; mean age at surgery 14.7 years). Diagnoses included adolescent (62.8%), juvenile (7.8%) and infantile (5.9%) idiopathic scoliosis, congenital (7.8%) and syndromic scoliosis (2%) and Scheuermann's kyphosis (13.7%). Mean (±SD) thoracic curvature was 61.3±15.2°, and mean kyphosis in those with Scheuermann's was 92.4±7.3°. No correlation was elicited between FEV1 or FVC (%predicted) and VO2peak(%pre-dicted). Greater thoracic curves were associated with lower FEV1(%predicted), r=À0.45, p=0.02, smaller total lung capacity (r=À0.47, p=0.002) and lower BR at the end of exercise (r=À0.57, p<0.0001). There was a positive correlation between FEV1(%predicted) and BR (r=0.65, p<0.001) and a negative correlation between FEV1 and VO2 at AT (r=À0.37, p=0.008). Those with higher VO2peak measures also had higher VO2 at AT (r=0.78, p£0.001). SRS-22 scores correlated significantly with VO2peak(%predicted) (total SRS-22 vs VO2peak(%predicted), r=0.50, p=0.006). Conclusion Contrary to previously published data, those with larger thoracic curves and therefore poorer lung function show improved exercise capacity and later onset AT, likely as a consequence of improved physical conditioning. These patients also report better quality of life, which may be due to maintenance of normal exercise levels. These findings suggest that physical adaptation occurs in scoliosis with impaired lung function, and that this may be protective to patients' mental health. Background Haemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome which can complicate sepsis, malignancy or autoimmune disease and may lead rapidly to critical illness and death. Early treatment reduces mortality but diagnosis requires a high index of suspicion and correct interpretation of laboratory results. Highly elevated ferritin levels (HEF) >10,000 mg/L are highly specific for HLH and should prompt consideration/exclusion of hyperinflammation. Diagnostic guidelines for HLH were published in 2004 requiring the presence of !5/8 criteria. Aim To assess recognition of HLH in a paediatric population with HEF. Methods This retrospective study was conducted at 8 UK centres. Biochemistry databases identified patients£16 years with serum ferritin >10,000 mg/L between 01.04.2014 and 31.03.2017. A standardised proforma was used to collect data. Cases were assessed against the 2004 HLH criteria. Due to limited access to some laboratory tests, modified criteria using a threshold of !4/5 (excluding tissue haemophagocytosis, decreased natural killer cell function, increased soluble interleukin-2 receptor) were also applied. Results Ninety-four patients (60.6% male) were identified. 36% were aged <1 year, 16% 1-5 years, 34% 6-12 years and 14% 13-16 years. Management was in neonatal/paediatric intensive care in 49.4%. Diagnoses included: infections (29.8%), malignancies (21.3%), rheumatological (13.8%), immunological (9.6%) and cardiac surgery (6.4%). A diagnosis of HLH was made by the treating clinical team in 30.9% and considered in the differential in a further 18.1%. Just 5 patients had complete data available to score against all 8 2004 HLH criteria whereas 49 patients had data to score against the modified criteria. Using all available data:
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. 14/94 (14.9%) met !5/8 criteria and all these patients were diagnosed with HLH by the treating team. . 33 (35.1%) met !4/5 criteria and 17 (51.5%) of these were diagnosed with HLH by clinicians. HLH was not documented as being considered in the differential in 11 (33.3%)
Overall mortality was 33.0% (31/94) but was 17.2% (5/29) in those patients diagnosed with HLH during their admission. Conclusion Although HEF is highly specific for HLH, the diagnosis was made or considered in just half of paediatric patients with this laboratory result. Increased awareness of this potentially-lethal condition is likely to lead to earlier treatment and reduced mortality.
